FDA head: Generic biotech drugs may not have to go through trials

12/15/2003 | Reuters

The FDA is studying whether it has the authority to approve generic versions of biotech drugs once the brand-name patents expire and without subjecting the generics to the same lengthy clinical trials. Commissioner Mark McClellan said the agency will soon put the notion forth as a proposal for public comment.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC